Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-04-18
2006-04-18
Murphy, Joseph (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S006120, C435S007100, C435S069100, C435S320100, C435S173300, C435S325000, C435S235100, C435S375000, C530S300000, C530S350000, C530S351000, C536S023100
Reexamination Certificate
active
07029861
ABSTRACT:
The present invention describes a mutant TLR-4 in mice that does not recognize endotoxin and therefore does not stimulate the secretion of TNF from macrophages. Methods of detecting the mutation are provided; as are methods screening for drugs that may stimulate TNF production. Finally methods of incorporating and expressing the mutant TLR-4 genes into a host cell are contemplated.
REFERENCES:
patent: 4215051 (1980-07-01), Schroeder et al.
patent: 4554101 (1985-11-01), Hopp
patent: 4603102 (1986-07-01), Himmelmann et al.
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 4800159 (1989-01-01), Mullis et al.
patent: 4883750 (1989-11-01), Whiteley et al.
patent: 5464937 (1995-11-01), Sims et al.
patent: 5488032 (1996-01-01), Dower et al.
patent: 5508262 (1996-04-01), Norman, Jr.
patent: 5608035 (1997-03-01), Yanofsky et al.
patent: 5726148 (1998-03-01), Katoh et al.
patent: 5767064 (1998-06-01), Sims et al.
patent: 5767234 (1998-06-01), Yanofsky et al.
patent: 5776731 (1998-07-01), Parnet et al.
patent: 5786331 (1998-07-01), Barrett et al.
patent: 320 308 (1989-06-01), None
patent: 329 822 (1990-10-01), None
patent: WO 89/06700 (1989-07-01), None
patent: WO 90/07641 (1990-07-01), None
Bell, et al., “A high-resolution map of the brown (b, Tyrp1) deletion complex of mouse Chromosome 4,”Mammalian Genome.6, 389-395, 1995.
Beutler et al., “Cachectin/tumor necrosis factor: Production, distribution and metabolic fate in vivo,”J. Immunol.,135:3972-3977, 1985.
Beutler et al., “Passive immunization against cachetin/tumor necrosis factor protects mice from lethal effect of endotoxin,”Science,229:869-871, 1985.
Beutler et al., “Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance,”Science,232:977-980, 1986.
Burn et al., “Increased exon-trapping efficency through modifications to the pSPL3 splicing vector,”Gene.161, 183-187, 1995.
Chaudhary et al. “Cloning and characterization of two toll/interleukin-1 receptor-like genes TIL3 and TIL4: evidence for a multi-gene receptor family in humans,”Blood.91, 4020-4027, 1998.
Cseh and Beutler, “Alternate cleavage of the cachectin/tumor necrosis factor propeptide results in a larger, inactive form of secreted protein, ”J. Biol. Chem.264, 16256-16260, 1989.
Geppert et al., “Lipopolysaccharide signals activation of tumor necrosis factor biosynthesis through the ras/raf-1/MEK/MAPK pathway,”Mol. Med.,1:93-103, 1994.
Gerard, “For whom the bell tolls,”Nature,395:217-219, 1998.
Han et al., “Endotoxin-responsive sequences control cachectin/tumor necrosis factor biosynthesis at the translation level,”J. Exp. Med.,171:465-475, 1990.
Hayes and Zoon, “Priming of human monocytes for enhanced lipopolysaccharide responses: expression of alpha interferon, interferon regulatory factors, and tumor necrosis factor,”Infec. Immun.,61:3222-3227, 1993.
Haziot et al., “Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD 14-deficient mice,”Immunity,4:407-414, 1996.
Heine et al., “Cutting edge: cells that carry a null allele for toll-like receptor 2 are capable of responding to endotoxin,”J. Immunology,162:6971-6975, 1999.
Hirsch et al., “Identifcation of positive and negative regulatory elements governing cell-type-specific expression of the neural cell adhesion molecule gene,”Mol Cell Biol.May 1990; 10(5):1959-1968, 1990.
Hoshino et al., “Cutting Edge: Toll-Like Receptor 4 (TLR4)—Deficient Mice Are Hyporesponsive to Lipoplysaccharide: Evidence for TLR4 as the Lps Gene Product,”Journal of Immunology,162:3749-3752, 1999.
Hu et al., “Resistance to salmonellosis in the chicken is linked to NRAMPI and TNC,”Genome Research.7, 693-704, 1997.
Kawai et al., “Unresponsiveness of MyD88-deficient mice to endotoxin,”Immunity,11(1):115-122, 1999.
Kirkland et al., Identification of lipopolysaccharide-binding proteins in 70Z/3 cells of photoaffinity cross-linking,J. Biol. Chem.,265:9520-9525, 1990.
Kirschning et al., “human toll-like receptor 2 confers responsiveness to bacterial lipopolysaccharide,”J. Exp. Med.,188:2091-2097, 1998.
Kruys et al., “Constitutive activity of the tumor necrosis factor promoter is canceled by the 3' untranslated region in nonmacrophage cell lines; a transdominant factor overcomes this suppressive effect,”Proc. Natl. Acad. Sci. USA,89:673-677, 1992.
Kuhns et al., “Endotoxin and IL-1 hyporesponsiveness in a patient with recurrent bacterial infections,” ABSTRACT,J. Immunol.158, 3959-3964, 1997.
Lemaitre et al., “The dorsoventral regulatory gene cassettespatzle/Toll/cactuscontrols the potent antifungal response indrosophiliaadults,”Cell.86, 973-983, 1996.
Macela et al., “The immune response againstFrancisella tularensislive vaccine strain in Lpsnand Lpsdmice,”FEMS Immunol. Med. Microbiol.13, 235-238, 1996.
Matsuura and Galanos, “Induction of hypersensitivity to endotoxin and tumor necrosis factor by sublethal infection withSalmonella typhimurium,” Infec. Immun.,58:935-937, 1990.
Medzhitov et al., “A human homologue of theDrosophiliaToll protein signals activation of adaptive immunity,”Nature,388:394-397, 1997.
Medzhitov et al., “MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways,”Molecular Cell,2:253-258, 1998.
Modlin et al., “The toll of innate immunity on microbial pathogens,”N. Engl. J. Med.,340:1834-1835, 1999.
Muzio et al., “The human toll signaling pathway: divergence of nuclear factor κB and JNK/SAPK activation upstream of tumor necrosis factor receptor-associated factor 6 (TRAF6),”J. Exp. Med.187, 2097-2101, 1998.
Poltorak et al., “Genetic and physical mapping of the Lps locus: identification of the Toll-4 receptor as a candidate gene in the critical region,”Blood Cells Molecules&Diseases,240(170):340-355, 1998.
Poltorak et al., “Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene,”Science,282:2085-2088, 1998.
Qureshi et al., “Endotoxin-tolerant mice have mutations in toll-like receptor 4 (Tlr4),”J Exp. Med.,189:615-625, 1999.
Rock et al., “A family of human receptors structurally related toDrosophilaToll,”Proc. Natl. Acad. Sci. U.S.A.95, 588-593, 1998.
Rommens et al., In: Hochgeschwender, U., Gardiner, K., eds.,Identification of Transcribed Sequences,“Towards a transcriptional map of the q21-q22 region of chromosome 7,” New York, N.Y., Plenum Press, 1998, p. 65.
Rosetto et al., “Signals from the IL-1 receptor homolog, toll, can activate an immune response in adrosophilahemocyte cell line,”Biochem. Biophys. Res. Commun.209, 111-116, 1995.
Schneider et al., “Dominant and recessive mutations define functional domains ofToll, a transmembrane protien required for dorsal-ventral polarity in theDrosophiliaembryo,”Genes Dev.,5:797-807, 1991.
Shimazu et al., “MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4,”J. Exp. Med.,189(11):1777-1782, 1999.
Tracey et al., “Shock and tissue induced by recombinant human cachectin,”Science,234:470-474, 1986.
Vogel et al., “Construction of a BALB/c congenic mouse, C.C3H-Lpsd, that expresses the Lpsdallele: analysis of chromosome 4 markers surrounding the Lps gene,”Infect.Immun.62, 4454-4459, 1994.
Wright et al., “CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein,”Science,249:1431-1433, 1990.
Yang et al., “Toll-like receptor-2 mediates lipopolysaccharide-induced cellular signalling,”Nature,395:284-288, 1998.
Beutler Bruce A.
Poltorak Alexander
Basi Nirmal S.
Board of Regents , The University of Texas System
Fulbright & Jaworski
Murphy Joseph
LandOfFree
LPS-response gene compositions and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with LPS-response gene compositions and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and LPS-response gene compositions and methods will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3536106